Research Use Only
Tirzepatide vs Retatrutide
Neutral RUO comparison of Tirzepatide and Retatrutide using public protocol-library fields: vial size, research class, mechanism, evidence level and references.
Public fields onlyReferences included
This page compares only public, research-context fields from the AllPeptides protocol library. It is not a ranking, recommendation, safety comparison or human-use guide.
Public research comparison fields
| Field | Tirzepatide | Retatrutide |
|---|---|---|
| Name | Tirzepatide | Retatrutide |
| Representative vial size | 5mg | 5mg |
| Research class | Metabolic research | Metabolic research |
| Mechanism context | Tirzepatide is a novel dual agonist that simultaneously activates the GLP-1 and GIP receptors. This dual mechanism enhances glucose-dependent insulin secretion while suppressing glucagon release, slowing gastric emptying and promoting satiety through central appetite regulation. The additional GIP activity synergistically enhances metabolic effects beyond GLP-1 alone, contributing to the superior weight reduction observed in clinical trials. A half-life of ~5 days allows convenient weekly administration. | Retatrutide is the first triple agonist that simultaneously activates three key metabolic hormone receptors: GLP-1, GIP and glucagon. This triple mechanism produces synergistic effects on appetite suppression, energy expenditure and glucose metabolism. The GLP-1 component reduces appetite and slows gastric emptying; GIP enhances insulin secretion and supports fat metabolism; glucagon receptor activation increases energy expenditure and promotes fat oxidation. In clinical trials, participants receiving 12 mg weekly recorded a mean change of 24% in their body weight over 48 weeks. |
| Evidence level | Not specified in profile | Not specified in profile |
Combined references
- StatPearls (NCBI Bookshelf) — Pharmacology, dosing and clinical use of Tirzepatide
View source - Frontiers in Endocrinology (2022) — GIP/GLP-1 agonist tirzepatide for type 2 diabetes and obesity
View source - The Lancet (2018) — Clinical data and safety of tirzepatide in type 2 diabetes (Phase 2)
View source - New England Journal of Medicine (2022) — Tirzepatide once weekly in a clinical obesity study
View source - FDA Prescribing Information — Mounjaro (tirzepatide) prescribing information
View source - Mayo Clinic — Tirzepatide — clinical overview and patient information
View source - New England Journal of Medicine (2023) — Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2, 48 weeks
View source - JAMA Network (2023) — Retatrutide Phase 2: 24% weight change at 12 mg weekly
View source - The Lancet (2023) — Retatrutide in type 2 diabetes: Phase 2 (weight change and glycemic outcomes)
View source - Katsi V et al. Biomolecules 2025 — Retatrutide-A Game Changer in Obesity Pharmacotherapy.
View source - Abdrabou Abouelmagd A et al. Proc (Bayl Univ Med Cent) 2025 — Efficacy and safety of retatrutide in obesity: systematic review and meta-analysis.
View source - Nature Reviews Endocrinology (2024) — Triple agonists for obesity and diabetes: clinical overview
View source